PERSIST trial: PrEP injections for HIV prevention
Part of Infections clinical trials.
This study gives long-acting cabotegravir injections (a shot every 2 months) to people at high risk of HIV. It aims to see if this new prevention method works well in real-world settings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 15 years old or older
- You are at high risk for HIV (e.g., a female sex worker, a man who has sex with men, a transgender person, a breastfeeding woman, or a woman seeking STI or family planning services)
- You are willing to get an injection every 2 months and come for HIV tests every 3 months
- You do not have HIV or possible early HIV infection
- You have not had a serious allergic reaction to cabotegravir before
- You are not currently taking medicines for multi-drug resistant tuberculosis or post-exposure prophylaxis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This research studies how two types of long-acting birth control (a shot called cabotegravir and an implant) work in your body after pregnancy, and how they interact with HIV prevention or treatment. The study helps doctors understand the best doses and timing for women like you.
This trial tests a long-acting injectable HIV prevention medication (cabotegravir) as an alternative to daily pills. It may be a good fit if you are a man who has sex with men and have been taking oral PrEP consistently.
This study looks at a long-acting injectable HIV prevention medication (called cabotegravir) to see how well it works in real life. If you are already taking or starting this shot, you may be able to join and help improve HIV prevention care.
This Phase 3 study tests whether an injectable HIV prevention medicine (cabotegravir) given before exposure can help prevent HIV in people at higher risk. You may join if you are HIV-negative and meet specific sexual health, medication, and health-testing requirements.
This study tests a nurse-led program that offers a long-acting injectable medication (cabotegravir) to prevent HIV. The injection is given every two months, and the program aims to make it easier to access this prevention option at your local health center.
This study offers three ways to prevent HIV: a shot every two months (injectable PrEP), daily pills, or a vaginal ring. Researchers in Cape Town will help you choose the option that fits your life best.
Hear when a new Long-acting Injectable Cabotegravir for PrEP trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.